Purple Biotech's IM1240 shows improved safety, increased exposure in toxicology study.

Purple Biotech announced the successful completion of a non-human primates toxicology study for IM1240, a tri-specific antibody targeting the tumor-specific antigen 5T4. The study showed improved safety at doses up to 300-fold higher than a non-capped comparator and demonstrated a prolonged circulating half-life due to its human serum albumin moiety and capping design. IM1240 is on track for first-in-human clinical trials, with a planned regulatory submission for the second half of 2026.